Lymphoma  >>  molibresib (GSK525762)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
molibresib (GSK525762) / GSK
NCT01943851: A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Hourglass Jul 2020 - Dec 2020 : In hematologic malignancies
Checkmark Initiation of expansion cohorts in P1 trial in hematologic malignancies
Jun 2017 - Jun 2017: Initiation of expansion cohorts in P1 trial in hematologic malignancies
Completed
2
111
Europe, US, RoW
GSK525762
GlaxoSmithKline
Neoplasms
04/20
04/20

Download Options